Markets:

Overview

News

Currencies

International

Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

4.285 +0.155 (+3.75%)

Streaming Delayed Price Updated: 12:02 PM EDT, Mar 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Nasdaq, S&P 500 Futures Rise As Nvidia GTC, Iran Tensions, Fed Meet Loom: Why META, MU, SOC, ALDX Are Also In Focus Today ↗

Today 5:01 EDT

Data from Stocktwits indicated that retail sentiment remains bearish on SPY and QQQ.

Via Stocktwits

ALDX Stock Garners Retail Interest: Investors Debate Dry Eye Treatment Approval Amid Long Wait ↗

March 10, 2026

The U.S. Food and Drug Administration is slated to rule on the company’s application seeking approval for Reproxalap by March 16.

Via Stocktwits

SSR Mining Stock Up 180% as New $5 Million Stake Signals Gold Conviction ↗

March 03, 2026

SSR Mining runs a diversified portfolio of gold, silver, and base metal mines across four continents with a vertically integrated model.

Via The Motley Fool

Topics ETFs Regulatory Compliance

Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy ↗

March 03, 2026

This clinical-stage biotech advances oncology therapies with a pipeline of novel small molecule inhibitors for hard-to-treat cancers.

Via The Motley Fool

Topics Regulatory Compliance

Keep an eye on the top gainers and losers in Tuesday's session. ↗

December 16, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

These stocks are moving in today's session ↗

December 16, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision? ↗

December 16, 2025

The FDA delayed its decision on the dry eye drug Reproxalap to March 2026 without raising new issues, while review and labeling discussions continued.

Via Stocktwits

Aldeyra’s Experimental Drug Shows Promising Results In Mid-Stage Alcohol Hepatitis Trial ↗

October 28, 2025

Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation in the study, the company said.

Via Stocktwits

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals ↗

October 10, 2025

4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.

Via Benzinga

4 Biotech Stocks Seeing Explosive Momentum Gains ↗

October 07, 2025

The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be...

Via Benzinga

Topics ETFs Stocks

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 06, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

May 05, 2025

Via Benzinga

Unusual volume stocks are being observed in Monday's session. ↗

April 07, 2025

These stocks have an unusual volume in today's session

Via Chartmill

Which stocks are experiencing notable movement on Friday? ↗

April 04, 2025

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 04, 2025

Via Benzinga

What's going on in today's after hours session ↗

April 03, 2025

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 03, 2025

Via Benzinga

What's going on in today's session ↗

April 03, 2025

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Via Chartmill

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

April 03, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

11 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 03, 2025

Via Benzinga

The market is filled with gapping stocks in Thursday's session. ↗

April 03, 2025

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

Crude Oil Dips 7%; ISM Services PMI Falls In March ↗

April 03, 2025

Via Benzinga

Aldeyra Stock Slumps After FDA Says Investigational Drug For Dry Eyes Treatment Failed To Demonstrate Efficacy – Retail Stays Optimistic ↗

April 03, 2025

Aldeyra Therapeutics CEO Todd C Brady said the company looks forward to a potential application resubmission by mid-year 2025, pending positive results from ongoing clinical trials and discussions with...

Via Stocktwits

Topics Artificial Intelligence Bankruptcy

These stocks that are showing activity before the opening bell on Thursday. ↗

April 03, 2025

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

Dow Tumbles Over 1,100 Points; US Initial Jobless Claims Fall ↗

April 03, 2025

Via Benzinga

Topics Stocks

FDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns ↗

April 03, 2025

The FDA rejected Aldeyra's resubmission for reproxalap, citing efficacy concerns. The company plans another trial and aims to resubmit the NDA by mid-2025.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 03, 2025

Via Benzinga

Aldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30% ↗

August 08, 2024

Aldeyra Therapeutics announces successful results from its Phase 3 clinical trial of reproxalap. The results support a potential 2024 NDA resubmission.

Via Benzinga

ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024 ↗

May 03, 2024

ALDX stock results show that Aldeyra Therapeutics met analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying ↗

April 04, 2024

The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.